262 related articles for article (PubMed ID: 24748406)
1. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.
Zhang T; Yu TT; Zhang DM; Hou XM; Liu XJ; Zhao D; Shan L
Med Oncol; 2014 May; 31(5):963. PubMed ID: 24748406
[TBL] [Abstract][Full Text] [Related]
2. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.
Zhang Y; Ma M; Han B
Tumour Biol; 2014 Nov; 35(11):10833-9. PubMed ID: 25081375
[TBL] [Abstract][Full Text] [Related]
3. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
Ni SS; Zhang J; Zhao WL; Dong XC; Wang JL
Tumour Biol; 2013 Jun; 34(3):1813-8. PubMed ID: 23475633
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
6. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
Wei LX; Zhou RS; Xu HF; Wang JY; Yuan MH
Tumour Biol; 2013 Apr; 34(2):941-6. PubMed ID: 23264086
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.
Li H; Zhou RJ; Zhang GQ; Xu JP
Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668
[TBL] [Abstract][Full Text] [Related]
8. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
[TBL] [Abstract][Full Text] [Related]
10. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
Zhang Z; Guo Y
Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
[TBL] [Abstract][Full Text] [Related]
11. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
12. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
13. Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.
Song C; Gao Y; Tian Y; Han X; Chen Y; Tian DL
Tumour Biol; 2013 Jun; 34(3):1925-33. PubMed ID: 23512329
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.
Guo C; Shao R; Correa AM; Behrens C; Johnson FM; Raso MG; Prudkin L; Solis LM; Nunez MI; Fang B; Roth JA; Wistuba II; Swisher SG; Lin T; Pataer A
J Thorac Oncol; 2013 Mar; 8(3):301-8. PubMed ID: 23370317
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
[TBL] [Abstract][Full Text] [Related]
17. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
[TBL] [Abstract][Full Text] [Related]
19. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.
Scieglinska D; Gogler-Piglowska A; Butkiewicz D; Chekan M; Malusecka E; Harasim J; Habryka A; Krawczyk Z
Anticancer Res; 2014 Jun; 34(6):2833-40. PubMed ID: 24922646
[TBL] [Abstract][Full Text] [Related]
20. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
